COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ — Curasight A/S “Curasight” or the “Company” – (TICKER: CURAS) has today resolved on a new issue of shares with preferential rights for the Company’s existing shareholders of up to DKK 51.2 million before transaction costs (the “Rights…
Month: February 2024
COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ — Curasight A/S “Curasight” or the “Company” – (TICKER: CURAS) has today resolved on a new issue of shares with preferential rights for the Company’s existing shareholders of up to DKK 51.2 million before transaction costs (the “Rights…
COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ — Curasight A/S “Curasight” or the “Company” – (TICKER: CURAS) has today resolved on a new issue of shares with preferential rights for the Company’s existing shareholders of up to DKK 51.2 million before transaction costs (the “Rights…
Coming Phase I/IIa basket trial planned to include five select cancer indications Study will apply Curasight’s uPAR theranostic platform approach combining diagnosis (uTRACE®) and therapy (uTREAT®) First patients expected to be dosed in the beginning of 2025 with expected first efficacy…
Coming Phase I/IIa basket trial planned to include five select cancer indications Study will apply Curasight’s uPAR theranostic platform approach combining diagnosis (uTRACE®) and therapy (uTREAT®) First patients expected to be dosed in the beginning of 2025 with expected first efficacy…
Coming Phase I/IIa basket trial planned to include five select cancer indications Study will apply Curasight’s uPAR theranostic platform approach combining diagnosis (uTRACE®) and therapy (uTREAT®) First patients expected to be dosed in the beginning of 2025 with expected first efficacy…
Coming Phase I/IIa basket trial planned to include five select cancer indications Study will apply Curasight’s uPAR theranostic platform approach combining diagnosis (uTRACE®) and therapy (uTREAT®) First patients expected to be dosed in the beginning of 2025 with expected first efficacy…
BOSTON, Feb. 13, 2024 /PRNewswire/ — Apple’s Vision Pro has recently grabbed all the headlines in the spatial computing world, following years of hype and rumors of Apple bringing a headset to market. The Vision Pro is thought to be merely the opening salvo of the tech giant’s strategy,…
BOSTON, Feb. 13, 2024 /PRNewswire/ — Apple’s Vision Pro has recently grabbed all the headlines in the spatial computing world, following years of hype and rumors of Apple bringing a headset to market. The Vision Pro is thought to be merely the opening salvo of the tech giant’s strategy,…
Embracing Comprehensive Restructuring for a New Biopharmaceutical Era Continuing the Development of MGC Pharma’s Innovative Drug Portfolio LONDON, Feb. 13, 2024 /PRNewswire/ — MGC Pharmaceuticals Ltd (LSE: MXC), (OTC: MGCLF), (ASX: MXC) Rebrands as Argent BioPharma in Strategic…